TJ-M2010-5 | MyD88 inhibitor

TJ-M2010-5 (1357471-57-8) is an inhibitor of the toll-like receptor(TLR)/adaptor molecule myeloid differentiation factor 88 (MyD88) signaling pathway, crucial for inflammation and associated with the development of many inflammation-related cancers.¹ It ameliorates ischemia-reperfusion injury in various organ models including brain², liver³, and heart⁴. TJ-M2010-5 also suppressed proliferation, migration, and invasion in MCF-7 and MDA-MB-231 breast cancer cells.⁵ It prevented colitis-associated colorectal cancer by impairing myeloid-derived suppressor cells.⁶

References/Citations:

1. Xie et al. (2016), Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer; J. Natl. Cancer Inst. 108 djv364
2. Jiang et al. (2024), MyD88 Inhibition Attenuates Cerebral Ischemia-reperfusion Injury by Regulating the Inflammatory Response and Reducing Blood-brain Barrier Damage; Neuroscience 549 121
3. Zou et al. (2023), The Novel MyD88 Inhibitor TJ-M2010-5 Protects Against Hepatic Ischemia-reperfusion Injury by Suppressing Pyroptosis in Mice; Transplantation 107 392
4. Yang et al. (2022), TJ-M2010-5 Attenuates Severe Myocardial Ischemia/Reperfusion Injury in Heart Transplantation by Inhibiting MyD88 Homodimerization In Vivo; J. Cardiovasc. Transl. Res. 15 1366
5. Liu et al. (2020), The MyD88 inhibitor TJ-M2010-5 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3ß and MyD88/NF-kB signalling pathways; Exp. Cell Res. 394 112157
6. Wang et al. (2022), Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells; Invest. New Drugs 40 506